Objective Breast tumors are classified by several grading systems and divided into four main molecular subtypes: Luminal A, Luminal B, Triple negative/basal-like and HER2+. Since luminal A tumors tend to be ER+, their treatment often includes hormonal therapy. HER2+ tumors can be treated with Trastuzumab, an anti-Her2 receptor antibody. Hormonal therapies or Trastuzumab cannot be used for triple negative tumors, which are ER- and HER2-, and these are usually treated with a combination of surgery, radiotherapy and chemotherapy. There is an urgent need for new therapies to effectively treat different breast cancer subtypes. Translating basic knowledge on tumor cell biology into more effective diagnostic tools and improved treatments for patients remains difficult. The use of patient-derived xenografts (PDX) as preclinical models that recapitulate the complexity and heterogeneity of the human tumors should help to develop and successfully translate to the clinic new therapies. Our recent work provides genetic and pharmacological evidence showing that p38 MAPK inhibition cooperates with the chemotherapeutic agent cisplatin to reduce breast tumor size and malignancy in vivo. Our results support a potential therapeutic use for p38 MAPK inhibitors in combination with chemotherapeutic drugs. The idea is to use PDX of specific breast cancer subtypes for preclinical validation of a new drug combination therapy with potential benefit to patients, which can be confirmed in clinical trials. Fields of science medical and health sciencesclinical medicinesurgerynatural sciencesbiological sciencescell biologymedical and health sciencesclinical medicineoncologybreast cancer Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Topic(s) ERC-PoC-2015 - ERC Proof of Concept Grant Call for proposal ERC-2015-PoC See other projects for this call Funding Scheme ERC-POC - Proof of Concept Grant Coordinator FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) Net EU contribution € 149 995,00 Address Carrer baldiri reixac 10-12 parc scientific de barcelona 08028 Barcelona Spain See on map Region Este Cataluña Barcelona Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Beneficiaries (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) Spain Net EU contribution € 149 995,00 Address Carrer baldiri reixac 10-12 parc scientific de barcelona 08028 Barcelona See on map Region Este Cataluña Barcelona Activity type Research Organisations Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
